P21
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
P21 is a synthetic BDNF-mimetic peptide: designed to reproduce the neurotrophic action of brain-derived neurotrophic factor (BDNF), the brain’s master “grow and survive” signal for neurons. It’s described as CNTF-derived. Note the name collision: “P21” here is the peptide, not the cell-cycle protein p21^CIP1. It belongs to the cognitive cluster — pair with Semax for the better-evidenced nootropic peptides.
What does it do in my body?
P21 is claimed to cross the blood-brain barrier and act as a BDNF mimetic, stimulating neurogenesis (formation of new neurons) and supporting cognitive function. The draw is that BDNF itself is a large protein that doesn’t cross the BBB well or survive in circulation; a small, stable mimetic that reproduces the signal would be valuable — if the activity holds up.
How can it help me?
- Where the science stands: Preclinical/animal only; 0 studies cited, 0 human trials in the captured directory profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Not documented. No human trials means no human side-effect profile exists in the record this KB draws from.
Regulatory status: Research compound — not approved for human use. Tier D / encyclopedia-only. Plausible mechanism, essentially no captured primary evidence — frame as researcher-community interest with formal data still thin.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
None exists in the source material. With zero captured studies (human or animal) and no dosing convention documented, there is nothing honest to say here beyond: this is not a compound with a real-world protocol behind it. Treat any dosing claim you encounter elsewhere as unsourced until proven otherwise.
What should I avoid combining — and what's synergistic?
P21 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A synthetic BDNF-mimetic peptide with a plausible, valuable mechanism and essentially no captured primary evidence. Honest frame: researcher-community interest, formal data still thin to nonexistent.
| Class | Synthetic BDNF-mimetic peptide (CNTF-derived) |
| Mechanism (one line) | Claimed to cross the blood-brain barrier and mimic BDNF, stimulating neurogenesis |
| Evidence base | Preclinical/animal only; 0 studies cited, 0 human trials in the captured directory profile |
| Safety record | No human safety data captured |
| Regulatory status | Research compound; not approved for human use |
What it is
P21 is a synthetic BDNF-mimetic peptide: designed to reproduce the neurotrophic action of brain-derived neurotrophic factor (BDNF), the brain’s master “grow and survive” signal for neurons. It’s described as CNTF-derived. Note the name collision: “P21” here is the peptide, not the cell-cycle protein p21^CIP1. It belongs to the cognitive cluster — pair with Semax for the better-evidenced nootropic peptides.
How it works
P21 is claimed to cross the blood-brain barrier and act as a BDNF mimetic, stimulating neurogenesis (formation of new neurons) and supporting cognitive function. The draw is that BDNF itself is a large protein that doesn’t cross the BBB well or survive in circulation; a small, stable mimetic that reproduces the signal would be valuable — if the activity holds up.
What the research shows
The directory profile this article draws from lists 0 studies cited, 0 human trials, grading the evidence anecdotal, and states no published clinical studies were found on PubMed for P21. The 0035 deep-research categorization pass grades it Tier D, citing preclinical neurogenesis data only, no human trials — the specific preclinical reports behind the BDNF-mimetic claim are not attached in the captured profile, so even the animal-tier evidence is asserted rather than cited.
Real-world protocol
None exists in the source material. With zero captured studies (human or animal) and no dosing convention documented, there is nothing honest to say here beyond: this is not a compound with a real-world protocol behind it. Treat any dosing claim you encounter elsewhere as unsourced until proven otherwise.
Side effects & management
Not documented. No human trials means no human side-effect profile exists in the record this KB draws from.
Regulatory status
Research compound — not approved for human use. Tier D / encyclopedia-only. Plausible mechanism, essentially no captured primary evidence — frame as researcher-community interest with formal data still thin.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, CNTF-derived description
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, CNTF-derived description
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)